Literature DB >> 25540350

Complete Genome Sequence of Streptococcus agalactiae CNCTC 10/84, a Hypervirulent Sequence Type 26 Strain.

Thomas A Hooven1, Tara M Randis1, Sean C Daugherty2, Apurva Narechania3, Paul J Planet, Hervé Tettelin2, Adam J Ratner4.   

Abstract

Streptococcus agalactiae (group B Streptococcus [GBS]) is a human pathogen with a propensity to cause neonatal infections. We report the complete genome sequence of GBS strain CNCTC 10/84, a hypervirulent clinical isolate frequently used to study GBS pathogenesis. Comparative analysis of this sequence may shed light on novel pathogenic mechanisms.
Copyright © 2014 Hooven et al.

Entities:  

Year:  2014        PMID: 25540350      PMCID: PMC4276828          DOI: 10.1128/genomeA.01338-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Streptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of neonatal sepsis and an emerging pathogen in adults (1, 2). Complete genome sequences of several GBS strains have been reported, and comparative genomic analyses have been extremely valuable in understanding GBS evolution (3). The strain CNCTC 10/84 was originally isolated from human clinical samples by Wilkinson and designated 1169-NT1 (4). It has been characterized as capsular polysaccharide type V (5) and sequence type 26 (ST-26) (6). Because of its highly virulent phenotype in animal models and its overproduction of β-hemolysin/cytolysin (βHC), CNCTC 10/84 has been widely used in studies of GBS-host interactions over the past two decades (7–10). Genomic DNA from S. agalactiae CNCTC 10/84 (ATCC 49447; CCUG 29784) was sequenced using Illumina MiSeq sequencing (paired end 2 × 150 bp; 3,726,676 total reads; 142.5-bp average length; estimated genome coverage 260×). Reads were assembled using Celera Assembler version 7.0 (11), resulting in 9 scaffolds with a cumulative size of 1,988,721 bp. The remaining gaps were closed using PCR and Sanger sequencing. Annotation was performed using the IGS Prokaryotic Annotation Engine (12). The final GBS CNCTC 10/84 genome sequence is 2,013,842 bp, has a GC content of 35.4%, 80 tRNA genes, 7 rRNA operons, and 1,980 predicted coding sequences. We confirmed the ST-26 classification of CNCTC 10/84 using the PubMLST server (http://pubmlst.org/sagalactiae) (13). Consistent with prior reports, the CNCTC 10/84 genome sequence contains a capsular polysaccharide synthesis locus most similar to those of other type V strains. Prior studies suggested that CNCTC 10/84 is phenotypically similar to GBS strains deficient in the covRS (csrRS) two-component system (6). However, we noted the presence of an intact covRS locus as well as additional two-component systems. The GBS cyl locus (cylX-cylK) is responsible for the synthesis of the granadaene pigment and βHC (14, 15), which may be the same molecule (16). We found an intact cyl locus and promoter region in the CNCTC 10/84 genome. Other factors important in GBS-host interactions were present in the CNCTC 10/84 genome, including pilus biosynthesis machinery, a eukaryotic-like serine–threonine kinase/phosphatase pair, sortases, adhesins, and other predicted cell wall–anchored proteins. Comparative analysis of the GBS CNCTC 10/84 genome with other available GBS genomes may inspire testable hypotheses regarding the basis for this strain’s hypervirulence.

Nucleotide sequence accession number.

This whole-genome sequence and annotation are available at GenBank under the accession number CP006910.
  16 in total

1.  A whole-genome assembly of Drosophila.

Authors:  E W Myers; G G Sutton; A L Delcher; I M Dew; D P Fasulo; M J Flanigan; S A Kravitz; C M Mobarry; K H Reinert; K A Remington; E L Anson; R A Bolanos; H H Chou; C M Jordan; A L Halpern; S Lonardi; E M Beasley; R C Brandon; L Chen; P J Dunn; Z Lai; Y Liang; D R Nusskern; M Zhan; Q Zhang; X Zheng; G M Rubin; M D Adams; J C Venter
Journal:  Science       Date:  2000-03-24       Impact factor: 47.728

2.  Genetic basis for the beta-haemolytic/cytolytic activity of group B Streptococcus.

Authors:  C A Pritzlaff; J C Chang; S P Kuo; G S Tamura; C E Rubens; V Nizet
Journal:  Mol Microbiol       Date:  2001-01       Impact factor: 3.501

3.  Identification of genetic determinants for the hemolytic activity of Streptococcus agalactiae by ISS1 transposition.

Authors:  B Spellerberg; B Pohl; G Haase; S Martin; J Weber-Heynemann; R Lütticken
Journal:  J Bacteriol       Date:  1999-05       Impact factor: 3.490

4.  Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells.

Authors:  V Nizet; R L Gibson; E Y Chi; P E Framson; M Hulse; C E Rubens
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Epidemiologically and clinically relevant Group B Streptococcus isolates do not bind collagen but display enhanced binding to human fibrinogen.

Authors:  Shaynoor Dramsi; Eric Morello; Claire Poyart; Patrick Trieu-Cuot
Journal:  Microbes Infect       Date:  2012-07-24       Impact factor: 2.700

6.  Group B Streptococcus β-hemolysin/cytolysin breaches maternal-fetal barriers to cause preterm birth and intrauterine fetal demise in vivo.

Authors:  Tara M Randis; Shari E Gelber; Thomas A Hooven; Rosanna G Abellar; Leor H Akabas; Emma L Lewis; Lindsay B Walker; Leah M Byland; Victor Nizet; Adam J Ratner
Journal:  J Infect Dis       Date:  2014-01-28       Impact factor: 5.226

7.  Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis.

Authors:  Kelly S Doran; George Y Liu; Victor Nizet
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  BIGSdb: Scalable analysis of bacterial genome variation at the population level.

Authors:  Keith A Jolley; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2010-12-10       Impact factor: 3.169

9.  A hemolytic pigment of Group B Streptococcus allows bacterial penetration of human placenta.

Authors:  Christopher Whidbey; Maria Isabel Harrell; Kellie Burnside; Lisa Ngo; Alexis K Becraft; Lakshminarayan M Iyer; L Aravind; Jane Hitti; Kristina M Adams Waldorf; Lakshmi Rajagopal
Journal:  J Exp Med       Date:  2013-05-27       Impact factor: 14.307

10.  β-Hemolysin/cytolysin of Group B Streptococcus enhances host inflammation but is dispensable for establishment of urinary tract infection.

Authors:  Ritwij Kulkarni; Tara M Randis; Swati Antala; Alice Wang; Fábio E Amaral; Adam J Ratner
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more
  11 in total

1.  A Counterselectable Sucrose Sensitivity Marker Permits Efficient and Flexible Mutagenesis in Streptococcus agalactiae.

Authors:  Thomas A Hooven; Maryam Bonakdar; Anna B Chamby; Adam J Ratner
Journal:  Appl Environ Microbiol       Date:  2019-03-22       Impact factor: 4.792

2.  Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.

Authors:  Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner
Journal:  Vaccine       Date:  2017-02-02       Impact factor: 3.641

3.  Genetic Basis Underlying the Hyperhemolytic Phenotype of Streptococcus agalactiae Strain CNCTC10/84.

Authors:  Luchang Zhu; Stephen B Beres; Prasanti Yerramilli; Layne Pruitt; Concepcion C Cantu; Randall J Olsen; James M Musser
Journal:  J Bacteriol       Date:  2020-11-04       Impact factor: 3.490

4.  Genome-Wide Assessment of Streptococcus agalactiae Genes Required for Survival in Human Whole Blood and Plasma.

Authors:  Luchang Zhu; Prasanti Yerramilli; Layne Pruitt; Matthew Ojeda Saavedra; Concepcion C Cantu; Randall J Olsen; Stephen B Beres; Andrew S Waller; James M Musser
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

5.  Mast cell degranulation by a hemolytic lipid toxin decreases GBS colonization and infection.

Authors:  Claire Gendrin; Jay Vornhagen; Lisa Ngo; Christopher Whidbey; Erica Boldenow; Veronica Santana-Ufret; Morgan Clauson; Kellie Burnside; Dionne P Galloway; Kristina M. Adams Waldorf; Adrian M Piliponsky; Lakshmi Rajagopal
Journal:  Sci Adv       Date:  2015-07-17       Impact factor: 14.136

6.  Complete genome sequence of Streptococcus agalactiae strain GBS85147 serotype of type Ia isolated from human oropharynx.

Authors:  Edgar Lacerda de Aguiar; Diego César Batista Mariano; Marcus Vinícius Canário Viana; Leandro de Jesus Benevides; Flávia de Souza Rocha; Letícia de Castro Oliveira; Felipe Luiz Pereira; Fernanda Alves Dorella; Carlos Augusto Gomes Leal; Alex Fiorini de Carvalho; Gabriela Silva Santos; Ana Luiza Mattos-Guaraldi; Prescilla Emy Nagao; Siomar de Castro Soares; Syed Shah Hassan; Anne Cybele Pinto; Henrique César Pereira Figueiredo; Vasco Azevedo
Journal:  Stand Genomic Sci       Date:  2016-06-03

7.  Functional Insights into the High-Molecular-Mass Penicillin-Binding Proteins of Streptococcus agalactiae Revealed by Gene Deletion and Transposon Mutagenesis Analysis.

Authors:  Luchang Zhu; Prasanti Yerramilli; Layne Pruitt; Abhishek Mishra; Randall J Olsen; Stephen B Beres; Andrew S Waller; James M Musser
Journal:  J Bacteriol       Date:  2021-08-09       Impact factor: 3.490

8.  The Streptococcus agalactiae Stringent Response Enhances Virulence and Persistence in Human Blood.

Authors:  Thomas A Hooven; Andrew J Catomeris; Maryam Bonakdar; Luke J Tallon; Ivette Santana-Cruz; Sandra Ott; Sean C Daugherty; Hervé Tettelin; Adam J Ratner
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

9.  Improving the Sensitivity of Real-time PCR Detection of Group B Streptococcus Using Consensus Sequence-Derived Oligonucleotides.

Authors:  Ameneh Khatami; Tara M Randis; Anna Chamby; Thomas A Hooven; Margaret Gegick; Evan Suzman; Brady A'Hearn-Thomas; Andrew P Steenhoff; Adam J Ratner
Journal:  Open Forum Infect Dis       Date:  2018-07-07       Impact factor: 3.835

10.  Modeling Group B Streptococcus and Blood-Brain Barrier Interaction by Using Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells.

Authors:  Brandon J Kim; Olivia B Bee; Maura A McDonagh; Matthew J Stebbins; Sean P Palecek; Kelly S Doran; Eric V Shusta
Journal:  mSphere       Date:  2017-11-01       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.